# Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies

> **NCT03746704** · PHASE1 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 2 (actual)

## Conditions studied

- Advanced PD-L1 Positive Malignancies

## Interventions

- **DRUG:** 89Zr˗DFO˗REGN3504

## Key facts

- **NCT ID:** NCT03746704
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-04
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746704, "Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03746704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*